ProCE Banner Activity

MANIFEST-2 Update: Phase III Trial of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Conference Coverage
Slideset

Updated data from the phase III MANIFEST-2 trial comparing pelabresib plus ruxolitinib vs placebo plus ruxolitinib shows a significant improvement in SVR35 and improved symptoms, fibrosis, and anemia in patients with JAK inhibitor–naive myelofibrosis.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi